Evidence map›Paper›PMID 27034829›Full record

ReviewJournal of signal transduction2016

Thyroid Hormones as Renal Cell Cancer Regulators.

Łukasz Szymański, Damian Matak, Ewa Bartnik, Cezary Szczylik, Anna M Czarnecka

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of signal transduction, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Internist's tumour into thyroid: A case report.Journal of the West African College of Surgeons
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Łukasz SzymańskiDepartment of Oncology, Military Institute of Medicine, Szaserow 128, 04-141 Warsaw, Poland; Institute of Genetics and Biotechnology, Faculty of Biology, Warsaw University, Pawinskiego 5a, 02-106 Warsaw, Poland; Department of Microwave Safety, Military Institute of Hygiene and Epidemiology, Kozielska 4, 01-163 Warsaw, Poland.ORCID 0000-0003-0148-541X
Damian MatakDepartment of Oncology, Military Institute of Medicine, Szaserow 128, 04-141 Warsaw, Poland; School of Molecular Medicine, Medical University of Warsaw, Zwirki i Wigury 61, 02-091 Warsaw, Poland.
Ewa BartnikInstitute of Genetics and Biotechnology, Faculty of Biology, Warsaw University, Pawinskiego 5a, 02-106 Warsaw, Poland; Institute of Biochemistry and Biophysics, Pawinskiego 5a, 02-106 Warsaw, Poland.
Cezary SzczylikDepartment of Oncology, Military Institute of Medicine, Szaserow 128, 04-141 Warsaw, Poland.
Anna M CzarneckaDepartment of Oncology, Military Institute of Medicine, Szaserow 128, 04-141 Warsaw, Poland.
Wojskowy Instytut Medycyny Lotniczej · PLInstitute of Biochemistry and Biophysics, Polish Academy of Sciences · PLMedical University of Warsaw · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is known that thyroid hormone is an important regulator of cancer development and metastasis. What is more, changes across the genome, as well as alternative splicing, may affect the activity of the thyroid hormone receptors. Mechanism of action of the thyroid hormone is different in every cancer; therefore in this review thyroid hormone and its receptor are presented as a regulator of renal cell carcinoma.

Identifiers

PMID27034829
PMCPMC4808550
OpenAlexW2296158535

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.